Holta Life Sciences AS
ASDissolvedOrg 987004304Klingenberggata 7, 0161 OsloUtleie av egen eller leid fast eiendom ellers· NACE 68209Est. 2004 · 22 years old0 employeeshttps://www.holtalifesciences.com
Loading company…
Overview
Holta Life Sciences AS is a Norwegian AS based in Oslo, operating in the Utleie av egen eller leid fast eiendom ellers sector. Incorporated in 2004, the company has 0 employees and reported revenue of NOK 12.4m in its latest annual filing.
Revenue 2022
12.4M NOK
+315% vs 2021
EBITDA margin
−100.6 %
−306% vs 2021
Net profit 2022
-11.3M NOK
-2973% vs 2021
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
99.1 %
Very strongAmong the 10% highest rated companies in the industry
20182022
Liquidity ratioCurrent assets ÷ Short-term debt
128.0×
Very strongAmong the 10% highest rated companies in the industry
20182022
Return on assets (ROA)Net profit ÷ Total assets × 100
-5.3 %
Very weakAmong the 20% lowest rated companies in the industry
20182022
EBITDA — year on year
NOK millionsKey figures
Annual report 2022| Revenue | 12.4M NOK | +315% |
| EBITDA | -12.5M NOK | -306% |
| Net profit | -11.3M NOK | -2973% |
| Total assets | 214.7M NOK | -12% |
| Equity | 212.8M NOK | -5% |
| Employees | 0 | — |
Company information
Legal name
HOLTA LIFE SCIENCES AS
Org number
987004304
Legal form
Aksjeselskap
NACE code
Founded
23 June 2004 · 22 years
Share capital
NOK 200,000
Employees
0 (FTE)
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap. Styrets leder alene.
Company purpose
Å være et investeringsselskap rettet mot helserelaterte investeringer samt andre finansielle og industrielle investeringer.
(no translation available)
Contact
Address
Klingenberggata 7, 0161 Oslo
Website
https://www.holtalifesciences.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2022), Holta Life Sciences AS reported revenue of NOK 12.4m, an increase of 315% on the year before. The figures on this page draw on 5 annual filings covering 2018 to 2022. The bottom line showed a net loss of NOK 11.3m, and the EBITDA margin stood at -100.6%.
At the end of 2022, equity financed 99.1% of the balance sheet, and current assets covered short-term debt 128 times.
Financials
Revenue
NOK millionsEBITDA
NOK millionsIncome statement
NOK thousands| Item | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 12,445 | 2,999 | 56,342 | 11,597 | 12,391 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -12,519 | -3,087 | 56,254 | 11,493 | -12,463 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -12,519 | -3,087 | 56,254 | 11,493 | -12,463 |
| Net financials | -959 | 929 | -2 | 0 | -4 |
| Profit before tax | -13,478 | -2,158 | 56,252 | 11,493 | -12,467 |
| Tax | -2,191 | -2,551 | 5,905 | 2,284 | 1,444 |
| Net profit | -11,288 | 393 | 50,346 | 9,210 | -13,912 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
NOK thousands| Item | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Total assets | 214,663 | 242,727 | 244,885 | 191,920 | 370,751 |
| Equity | 212,776 | 224,063 | 227,684 | 182,241 | 367,318 |
| Long-term debt | 395 | 3,124 | 6,806 | 2,284 | 2,537 |
| Short-term debt | 1,492 | 15,540 | 10,395 | 7,394 | 897 |
| Total debt | 1,887 | 18,664 | 17,201 | 9,679 | 3,434 |
Financial ratios
5-year trendEBITDA margin
-100.6 %
20182022
Equity ratio
99.1 %
Very strongAmong the 10% highest rated companies in the industry
20182022
Return on equity
-5.3 %
WeakAmong the 30% lowest rated companies in the industry
20182022
Net profit margin
-90.7 %
Very weakAmong the 20% lowest rated companies in the industry
20182022
Asset turnover
0.06×
AverageAround the average of companies in the same industry
20182022
Debt / equity
0.01×
Very strongAmong the 10% highest rated companies in the industry
20182022
Sector performance
27 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Gross marginWeak
Among the 30% lowest rated companies in the industry
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginVery weak
Among the 10% lowest rated companies in the industry
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginVery weak
Among the 20% lowest rated companies in the industry
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Weak
Among the 30% lowest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Very weak
Among the 20% lowest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Weak
Among the 30% lowest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Very weak
Among the 20% lowest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioAverage
Around the average of companies in the same industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioVery strong
Among the 10% highest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioVery strong
Among the 10% highest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioVery weak
Among the 10% lowest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityWeak
Among the 40% lowest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalVery strong
Among the 20% highest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioStrong
Among the 40% highest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioVery strong
Among the 10% highest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioVery strong
Among the 10% highest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityVery strong
Among the 10% highest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityVery strong
Among the 20% highest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtVery weak
Among the 10% lowest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtVery weak
Among the 10% lowest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageVery weak
Among the 20% lowest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtVery weak
Among the 10% lowest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginVery weak
Among the 20% lowest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Asset turnoverAverage
Around the average of companies in the same industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Equity to contributed capitalVery strong
Among the 10% highest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityWeak
Among the 30% lowest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtVery strong
Among the 10% highest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Annual reports & filings
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
ET Chief Executive Officer | Chief Executive Officer | 2014 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
RM Board of Directors | Board of Directors | 2021 |
PA Board of Directors | Board of Directors | 2021 |
KH Chairman | Chairman | 2014 |
Former (2)
DT Board of Directors | Board of Directors | 2014 – 2021 |
LO Board of Directors | Board of Directors | 2014 – 2021 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 100% | 100% | 2020 |
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
Holta Invest As
Holta Life Sciences AS Board network connections
Board members of Holta Life Sciences AS also hold positions in 100 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Leif Ove Rørnes | Board of Directors | 34 companiesMany roles |
| Reidar Munthe-Kaas Tveiten | Board of Directors | 17 companiesMany roles |
| Pål Anders Westerheim | Board of Directors | 15 companiesMany roles |
| Kjetil Holta | Chairman | 15 companiesMany roles |
| Espen Tidemann Jørgensen | Chief Executive Officer | 10 companiesMany roles |
| Dag Teigland | Board of Directors | 9 companiesMany roles |
Frequently asked questions
What is the Org number of Holta Life Sciences AS?
Holta Life Sciences AS is registered with Brønnøysundsregistrene under Org 987004304.
What is the revenue of Holta Life Sciences AS?
Holta Life Sciences AS reported revenue of NOK 12.4m in 2022.
Who is the CEO of Holta Life Sciences AS?
Espen Tidemann Jørgensen is the CEO of Holta Life Sciences AS, in role since 2014.
Who is the chairman of Holta Life Sciences AS?
Kjetil Holta chairs the board of Holta Life Sciences AS, in role since 2014.
Where is Holta Life Sciences AS headquartered?
Holta Life Sciences AS's registered address is Klingenberggata 7.